SDM-Webinar-header---EN

Webinar series: shared decision-making for hemophilia treatment

The World Federation of Hemophilia (WFH) Shared Decision Making (SDM) tool helps clinicians and patients work together to make treatment decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values. This February and March, join us online to learn more about why it is important for people with hemophilia (PWH) to be included in their treatment decisions.

Also available in: Français Español

The three-part webinar series will cover the factor and non-factor treatments available for hemophilia, such as standard half-life (SHL), extended half-life (EHL), bispecific antibody, and rebalancing agent products, and gene therapy. We will cover how to consider the benefits and risks of each treatment, as well as the advantages of using SDM for people with hemophilia and for healthcare providers. The third webinar will share real-life experiences of physicians and PWH using the WFH SDM Tool. The presentations will be followed by an extensive Q&A period.

The three 90-minute sessions will take place on:

This webinar series is relevant for people with hemophilia, healthcare providers, and national member organization (NMO) members. Presentations will be given in English, with live interpretation offered in Spanish and French.

To learn more about the WFH SDM Tool and the multiple treatment options, click here. Ready to register for the webinars? Click here!

The WFH thanks our Corporate Partners BioMarin Pharmaceutical Inc., CSL Behring, F. Hoffmann-La Roche, Novo Nordisk, Pfizer, Sanofi and Sobi.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.